Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 856 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HER-2 Positive Breast Cancer Clear all

Conditions: Breast Cancer
Interventions: Letrozole, Ribociclib, Placebo; Drug
Lead sponsor: Qamar Khan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 13
States / cities: Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more

Conditions: Breast Cancer
Interventions: Ribociclib, Anastrozole, Letrozole, Goserelin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more

Conditions: Breast Neoplasms
Interventions: PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more

Conditions: Breast Cancer
Interventions: trastuzumab (Herceptin®); Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Metastatic Breast Cancer
Interventions: Ribociclib, Tamoxifen, Letrozole, Anastrozole, Goserelin, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 35
States / cities: Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more

Conditions: Breast Cancer, HER2-positive Breast Cancer
Interventions: trastuzumab-emtansine, Trastuzumab SC, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 53
States / cities: San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more

Conditions: Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
Interventions: Anastrozole, Denifanstat, Exemestane, Fulvestrant, Echocardiography, Letrozole, Paclitaxel, Trastuzumab, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy; Drug · Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Metastatic Breast Cancer
Interventions: Erlotinib; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HER2 Positive Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Comprehensive Geriatric Assessment, Laboratory Biomarker Analysis, Neratinib, Pharmacological Study; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Corona, California • Duarte, California • Lancaster, California + 4 more

Conditions: Breast Cancer, Invasive Breast Cancer
Interventions: Anastrozole, Letrozole, Exemestane, Tamoxifen; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
Interventions: Ibrutinib, Durvalumab; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions: Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin; Drug · Biological
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer, Metastatic, HER2 + Breast Cancer
Interventions: Trastuzumab (Herceptin), SIgnatera; Drug · Diagnostic Test
Lead sponsor: Nagoya City University; Other
Eligibility: 20 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Carlos, Texas

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions: NUV-422, Fulvestrant; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more

Conditions: Breast Cancer
Interventions: BMS-690514, Lapatinib, Letrozole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Abilene, Texas • Beaumont, Texas • Fort Worth, Texas + 1 more

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 47
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more

Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Interventions: Neratinib, Fulvestrant, Trastuzumab, Paclitaxel; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more

Conditions: Breast Cancer
Interventions: lapatinib ditosylate, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, cell sorting, immunohistochemistry staining method, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 9
States / cities: Cleveland, Ohio

Conditions: Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
Interventions: BT8009, Pembrolizumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more

Conditions: Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 8
States / cities: Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hormone-receptor-positive Breast Cancer, HER2-low Breast Cancer, HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
Interventions: Alpelisib, Tamoxifen, Zotatifin, Fulvestrant; Drug
Lead sponsor: Jennifer Lee Caswell-Jin; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 38
States / cities: Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more

Search by objective public record fields.

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

ATEMPT 2.0: Adjuvant T-DM1 vs TH

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Lapatinib Resistance in Patients With Breast Cancer

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)